We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Multiplex Real-Time PCR Assay Simultaneously Detects and Identifies 9 Parasitic Gastrointestinal Pathogens

By LabMedica International staff writers
Posted on 12 May 2023
Print article
Image: The Allplex GI-Helminth(I) Assay is the first marketed multiplex PCR for helminth diagnosis (Photo courtesy of Seegene)
Image: The Allplex GI-Helminth(I) Assay is the first marketed multiplex PCR for helminth diagnosis (Photo courtesy of Seegene)

The field of parasitology has seen a growing interest in molecular biology. Molecular tools have been extensively used in disciplines such as bacteriology and virology, but the identification of intestinal parasites has been hampered by technical hurdles. Specifically, working with stool samples can be problematic due to the high presence of inhibitors that can disrupt PCR reactions. A novel multiplex PCR assay that allows for the reliable and efficient detection of numerous parasites in a single testing run marks a significant milestone in the field of parasitology.

Seegene, Inc.’s (Seoul, Korea) Allplex GI-Helminth(I) Assay is the first commercially available multiplex PCR assay for the identification of helminths in human stool samples. The assay makes it possible to simultaneously detect and identify nine gastrointestinal parasitic pathogens using real-time PCR. The Allplex GI-Helminth(I) Assay can detect one protozoan and eight helminths, all of which are highly pathogenic parasites. The assay, based on Seegene’s exclusive MuDT technology, provides multiple Ct values for each pathogen in a single channel using real-time PCR instrumentation.

By enabling the simultaneous detection of full range of common intestinal parasites, the informative assay assists in appropriate treatment and management for co-infection. In addition, accurate test results allow for quick and proper treatment. The assay offers a convenient workflow using Seegene’s automated One platform, along with automated data interpretation and LIS interlocking with Seegene Viewer.

Related Links:
Seegene, Inc.

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more